Company intelligence / Profile preview
Alcresta Therapeutics
Waltham, Massachusetts, United Statesalcresta.com ↗
- Ownership
- Private
- Employees
- ~41
- Development stage
- Commercial
01
Overview
RELiZORB, the company’s lead product, has achieved FDA clearance and commercial launch. It improves fat absorption in enterally fed patients with rare diseases causing fat malabsorption. Next-generation RELiZORB was FDA-cleared in December 2023 and commercially launched in May 2024. Clinical trials are ongoing to expand indications and patient populations.
- Therapeutic areas
- GastroenterologyPulmonology
- Modalities
- Enzyme replacement therapyDevice (digestive enzyme cartridge)Recombinant protein (lipase enzyme)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Boston Children’s Hospital (preclinical/clinical research collaboration on ALC‑078); no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Alcresta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alcresta Therapeutics.